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Background: PKCe, a kinase widely implicated in tumorigenesis and metastasis, is overexpressed in many cancers.
Results: Transcription factors Sp1 and STAT1 control the expression of PKCe in cancer cells.
Conclusion: Up-regulation of PKCe is mediated by dysregulated transcriptional mechanisms.
Significance:Our results may have significant implications for the development of approaches to target PKCe and its effectors
in cancer therapeutics.
Overexpression of PKCe, a kinase associated with tumor
aggressiveness and widely implicated in malignant transforma-
tion andmetastasis, is a hallmark of multiple cancers, including
mammary, prostate, and lung cancer. To characterize themech-
anisms that control PKCe expression and its up-regulation in
cancer, we cloned an;1.6-kb promoter segment of the human
PKCe gene (PRKCE) that displays elevated transcriptional activ-
ity in cancer cells. A comprehensive deletional analysis estab-
lished two regions rich in Sp1 and STAT1 sites located between
2777 and2105bp (regionA) and2921 and2796bp (regionB),
respectively, as responsible for the high transcriptional activity
observed in cancer cells. A more detailed mutagenesis analysis
followed by EMSA and ChIP identified Sp1 sites in positions
2668/2659 and2269/2247 as well as STAT1 sites in positions
2880/2869 and 2793/2782 as the elements responsible for
elevated promoter activity in breast cancer cells relative to nor-
mal mammary epithelial cells. RNAi silencing of Sp1 and
STAT1 in breast cancer cells reduced PKCemRNA and protein
expression, as well as PRKCE promoter activity. Moreover, a
strong correlation was found between PKCe and phospho-Ser-
727 (active) STAT1 levels in breast cancer cells. Our resultsmay
have significant implications for the development of approaches
to target PKCe and its effectors in cancer therapeutics.
The serine-threonine kinase protein kinase Ce (PKCe), a
phorbol ester receptor, has beenwidely implicated in numerous
cellular functions, including cell cycle progression, cytokine-
sis, cytoskeletal reorganization, ion channel control, and
transcription factor activity regulation (1–6). This ubiqui-
tously expressed kinase has been associated with multiple dis-
ease conditions, including obesity, diabetes, heart failure, neu-
rological diseases, and cancer (7–10). PKCe is primarily
activated by the lipid second messenger diacylglycerol (11), a
product of phosphatidylinositol 4,5-bisphosphate hydrolysis by
phospholipase C, which, like phorbol esters, binds to the C1
domains located in theN-terminal regulatory region. Receptors
coupled to diacylglycerol generation, including tyrosine kinase
andG-protein-coupled receptors, cause the intracellularmobi-
lization of PKCe to the plasmamembrane and other intracellu-
lar compartments, where it associates with interacting partners
and phosphorylates specific substrates (12).
It is widely recognized that distinct members of the diacyl-
glycerol/phorbol ester-regulated PKCs act either as promoters
or suppressors of growth and tumorigenesis (13, 14). In that
regard, work from several laboratories identified PKCe as an
oncogenic kinase and established important roles for this
kinase in the development and progression of cancer. Early
studies revealed that ectopic overexpression of PKCe leads to
malignant transformation in some cell types (11, 15, 16). PKCe
confers growth advantage and survival through the activation
of Ras/Raf/ERK, PI3K/Akt, STAT3, and NF-kB pathways (17,
18). PKCe alsomediates resistance to chemotherapeutic agents
and ionizing radiation, and inhibition of its activity or expres-
sion sensitizes cancer cells to cell death-inducing agents (19–
21). Most remarkably, PKCe emerged as a cancer biomarker, as
it is markedly up-regulated in most epithelial cancers (22, 23).
For example, the vast majority of prostate tumors, in particular
those from advanced and recurrent patients, display elevated
PKCe levels (24). Prostate-specific PKCe transgenic mice
develop prostatic neoplastic lesions with elevated Akt, STAT3,
and NF-kB activity (17). Another remarkable example of PKCe
up-regulation is in lung cancer; the vast majority (.90%) of
primary human non-small cell lung cancers show significant
PKCe overexpression compared with normal lung epithelium,
and knockdown of PKCe from non-small cell lung cancer cells
impairs their ability to form tumors and metastasize in nude
mice (25). Likewise, depletion of PKCe from breast cancer cells
impairs growth, tumorigenicity, and invasiveness. Accordingly,
PKCe up-regulation has been associated with poor disease-free
and overall survival of breast cancer patients (22). More
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recently, a PKCe ATP mimetic inhibitor was found to impair
the growth of breast cancer cells in vitro and in vivo, highlight-
ing the potential of PKCe as a breast cancer therapeutic target
(26). Regardless of the well accepted fact that disregulation in
PKCe expression plays a causative role in cancer progression,
little is known regarding the mechanisms that control the
expression of this pro-oncogenic andmetastatic kinase. To our
knowledge, the transcriptional mechanisms controlling the
expression of the PRKCE promoter in humans or other species
have not yet been studied. To characterize the regulation of
PKCe expression, we cloned a fragment of the promoter region
of the human PRKCE gene and investigated the critical deter-
minants controlling transcriptional activation of this gene. Our
analysis revealed key cis-acting elements in the PRKCE pro-
moter and candidate transcription factors, particularly Sp1 and
STAT1, that contribute to PKCe overexpression in breast can-
cer. Furthermore, we identified a self-controlled mechanism
that significantly contributes to the up-regulation of PKCe in
breast cancer cells.
EXPERIMENTAL PROCEDURES
Cell Culture—Mammary (MCF-10A, MCF-7, T-47D, BT-474,
HCC-1419, MDA-MB-231, MDA-MB-453, and MDA-MB-468),
prostate (RWPE-1, LNCaP, C2, C2-4, DU145, and PC3), and
lung (HBEC, H358, H1975, H1650, HCC827, PC9, H4006,
H460, and A549) cell lines were purchased from the American
Type Culture Collection (ATCC,Manassas, VA). PC3-ML cells
were a kind gift of Dr. Alessandro Fatatis (Drexel University).
Cancer cell lines were maintained in Dulbecco’s modified
Eagle’s medium (DMEM) or RPMI 1640 medium supple-
mented with 10% FBS, L-glutamine (500 mM), and penicillin/
streptomycin (100 units/100mg/ml).Normal immortalizedMCF-
10A, HBEC, and RWPE-1 cells were cultured as described
previously (18, 27). All cells were grown at 37 °C in a humidified
5% CO2 incubator.
Reagents—The PKC inhibitor GF 109203X was purchased
fromBiomol (PlymouthMeeting, PA). ActinomycinD,mithra-
mycin A, 5-aza-29-deoxycytidine, and trichostatin A were
obtained from Sigma.
Cloning of the Human PRKCE Promoter and Generation of
Luciferase Reporter Constructs—All primers used for PCRwere
purchased from Integrated DNA Technologies (IDT, Cor-
alville, IA). PRKCE promoter truncated fragments (21933/
1219, 21416/1219, 2808/1219, 2531/1219, 2401/1219,
2320/1219, and 2105/1219) were amplified by PCR from
human genomic DNA prepared from T-47D cells using BglII-
and NheI-flanked following primers and subcloned into the
pGL3-enhancer luciferase reporter vector (Promega, Madison,
WI). The following were used: pGL321933/1219, CGTGCT-
AGCCCAGACTTGACTTGGCAGAAG (forward) and TCG-
AGATCTGAAGGCCATTGAACACTACCATGGTCG (re-
verse); pGL321416/1219, CGTGCTAGCCTCGCAGCCTG-
CGAAGTCCAGGACAG (forward) and TCGAGATCTGAA-
GGCCATTGAACACTACCATGGTCG (reverse); pGL-
32808/1219, CGTGCTAGCCTGACGTCTTTTGCGCATT-
TCCTGC (forward) and TCGAGATCTGAAGGCCATTGA-
ACACTACCATGGTCG (reverse); pGL32531/1219, CGTG-
CTAGCGATGTGAGATTCCGGGCTCCT (forward) and
TCGAGATCTGAAGGCCATTGAACACTACCATGGTCG
(reverse); pGL32401/1219, CGTGCTAGCACCATTTCCT-
CTCGACATGC (forward) and TCGAGATCTGAAGGCCA-
TTGAACACTACCATGGTCG (reverse); pGL32320/1219,
CGTGCTAGCCGCTGAGTGTGCGAAGAGGATCCG (for-
ward) and TCGAGATCTGAAGGCCATTGAACACTACCA-
TGGTCG (reverse); and pGL32105/1219, CGTGCTAGCC-
GACAGCTCGTCTTCTCTTCTGGAG (forward) and TCG-
AGATCTGAAGGCCATTGAACACTACCATGGTCG (re-
verse). The pGL321416/1219 vector was used as a template to
generate a series of PRKCE promoter truncated luciferase
reporter vectors (21319/1219, 21224/1219, 21121/1219,
21032/1219, 21028/1219, 2921/1219, 2887/1219, 2873/
1219, 2819/1219, 2796/1219, and 2777/1219) with the
Erase-a-Base kit (Promega, Madison, WI). pGL32644/1219
was generated by digestion of pGL32808/1219 vector with
PfIMI and NheI and subsequent religation. All constructs were
verified by DNA sequencing.
Site-directed mutagenesis—For PCR-based mutagenesis, we
used the QuikChange XL site-directed mutagenesis kit (Strat-
agene, La Jolla, CA). pGL32921/1219 was used as a template
to generate deletional mutations of STAT1 sites using the fol-
lowing primers: 1) CTATCGATCTCACTTTCGTATTGCT-
CCCC (forward) and GGGGAGCAATACGAAAGTGAGAT-
CGATAG (reverse); 2) GGCAAAACTTTCTATCCCAAACA-
CTGCCG (forward) and CGGCAGTGTTTGGGATAGAAA-
GTTTTGCC (reverse); 3) GACGTCTTTTGCGCATCTGCA-
TTAGAGGGAG (forward) and CTCCCTCTAATGCAGAT-
GCGCAAAAGACGTC (reverse); 4) CTCCGAGGAGGACC-
ATCTCTCGACATGCATCCC (forward) and GGGATGCA-
TGTCGAGAGATGGTCCTCCTCGGAG (reverse); and 5)
CTCCCGGAGTCGAAATCCGGGATTATGTTTCG (forward)
and CGAAACATAATCCCGGATTTCGACTCCGGGAG (re-
verse).AllmutantconstructswereconfirmedbyDNAsequencing.
Transient Transfection and Luciferase Assays—Cells in 12-
well plates (;2 3 105 cells/well) were co-transfected with 450
ng of a PRKCE promoter Firefly luciferase reporter vector and
50 ng of the Renilla luciferase expression vector (pRL-TK)
using Lipofectamine 2000 (Invitrogen) or X-tremeGENEHP
DNA transfection reagent (Roche Applied Science). After 48 h,
cells were lysed with passive lysis buffer (Promega, Madison,
WI). Luciferase activity was determined in cell extracts using
the Dual-LuciferaseTM reporter assay kit (Promega). Data were
expressed as the ratio between Firefly and Renilla luciferase
activities. In each experiment, the pGL3-positive control vector
(Promega) was used as a control. Promoter activity of each
PRKCE promoter luciferase reporter construct was expressed
as follows: (Firefly (sample)/Renilla (sample))/(Firefly (posi-
tive)/Renilla (positive))3 100%.
Western Blot—Western blot analysis was carried out essen-
tially as described previously (28). Bands were visualized by the
ECLWestern blotting detection system. Images were captured
using a FujiFILM LAS-3000 system. The following antibodies
were used: anti-PKCe and anti-Sp1 (1:1000, Santa Cruz Bio-
technology Inc., Santa Cruz, CA); anti-STAT1 and anti-phos-
pho-STAT1 (Ser-727) (1:1000, Cell Signaling Technology Inc.,
Danvers, MA); and anti-vinculin and anti-b-actin (1:50,000,
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Sigma). Anti-mouse or anti-rabbit conjugatedwith horseradish
peroxidase (1:5000, Bio-Rad) was used as secondary antibodies.
RNA Interference—RNAi duplexes were transiently trans-
fected using Lipofectamine RNAiMax. For transient depletion of
PKCe, STAT1, and Sp1, we used ON-TARGET Plus RNAi
duplexes purchased from Dharmacon (Waltham, MA). Silencer
control RNAi from Ambion was used as a nontarget control.
Twenty four h after RNAi delivery, cells were transfected with
different luciferase reporters, and luciferase activity was deter-
mined 48 h later.
Real Time Quantitative PCR (qPCR)2—Total RNA was
extracted from subconfluent cell cultures using the RNeasy kit
(Qiagen, Valencia, CA). One mg of RNA/sample was reverse-
transcribed using the TaqMan reverse transcription reagent kit
(Applied Biosystems, Branchburg, NJ) with random hexamers
used as primers. PCR primers and a 59 end 6-carboxyfluores-
cein-labeled probe for PKCewere purchased fromApplied Bio-
systems. PCR was performed using an ABI PRISM 7700 detec-
tion system in a total volume of 25 ml containing TaqMan
universal PCR MasterMix (Applied Biosystems), commercial
target primers (300 nM), the fluorescent probe (200 nM), and 1
ml of cDNA. PCR product formation was continuously moni-
tored using the sequence detection system software version 1.7
(Applied Biosystems). The 6-carboxyfluorescein signal was
normalized to endogenous tRNA 18 S or ubiquitin C. DCt was
obtained by subtracting the circle threshold (CT) of tRNA 18 S
or ubiquitin C from that of PKCe. D(DCt) was determined by
subtracting the controlDCt from the sampleDCt. Fold-changes
were expressed as (2)2D(DCt).
RNA Stability Assay—53 105 cells seeded into 35-mmplates
were treated with actinomycin D (2.5 mg/ml) for 16 h. Total
RNA from different cell lines was extracted at different times
using TRIzol (Invitrogen). cDNA was synthesized using the
TaqMan reverse transcription reagent kit (Applied Biosys-
tems). PKCe mRNA levels were determined by qPCR as
described above. For each cell line, mRNA levels at time5 0 h
was set as 100%.
In Silico PKCemRNA Profiling in Breast Cancer Cells—A-
nalysis of PRKCE gene expression in breast cancer was done
from three independent studies (GSE10843, GSE12777, and
GSE41445) using inSilicoDb and inSilicoMerging R/Biocon-
ductor packages (29). These gene expression profiles were
developed using the Affymetrix HG -U133 Plus2 platform
(GPL570). Briefly, the frozen RMA preprocessed expression
profiles of these studies were downloaded from the InSilico
database and merged using the COMBAT algorithm as the
batch removal method. Visualization and statistical analysis of
PKCe expression profile were done with R.
Analysis of Methylation of the PRKCE Promoter—The
presence of CpG islands in the human PRKCE promoter
(NC_000002.11) was determined using the Methyl Primer
Express software (Applied BioSystems). For the analysis of
PKCe mRNA expression after demethylation, MCF-10A cells
were treated with different concentrations (1–100 mM) of
5-aza-29-deoxycytidine (96 h or 7 days) and/or trichostatin A
(100 ng/ml, 24 h). Total mRNA was extracted, and PKCe
mRNA levels were determined by qPCR as described above.
Electrophoretic Mobility Shift Assay (EMSA)—EMSA was
performed as described elsewhere (18). Briefly, nuclear and
cytosolic fractions were obtained after cell lysis using the NE-
PER nuclear protein extraction kit (Pierce). The following
probes were used: STAT1-2 oligonucleotide probes (sense 59-
AGCTTTTTCTATTTCCCCAAACACTGCCG-39 and anti-
sense, 59-AATTCCGGCAGTGTTTGGGGAAATAGAAA-
39); Sp1-2 oligonucleotide probe (sense 59-AGCTTAGCGCG-
GAGGGCGGGCGCCGGCGC-39 and antisense, 59-AATTC-
GCGCCGGCGCCCGCCCTCCGCGCT-39); STAT1 consensus
probe (sense, 59-AGCTTCATGTTATGCATATTCCTGTA-
AGTG and antisense, 59-AATTCCACTTACAGGAATATG-
CATAACATG-39); Sp1 consensus probe (sense, 59-AGCTTA-
TTCGATCGGGGCGGGGCGAGC-39 and antisense, 59-AATT-
CGCTCGCCCCGCCCCGATCGAAT-39). Probes were labeled
with [a-32P]deoxyadenosine triphosphate using Klenow
enzyme and purified on a Sephadex G-25 column. The binding
reaction was carried out at 25 °C for 10 min with or without
nuclear proteins (5 mg), poly(dI-dC) (1 mg), and labeled probe
(106 cpm) in 20 ml of binding buffer (103 buffer: 100 mM Tris-
HCl, pH 7.5, 500 mM NaCl, 50 mM MgCl2, 100 mM EDTA, 10
mM DTT, 1% Triton X-100, and 50% glycerol). Binding speci-
ficity was confirmed by cold competition with 50-fold molar
excess of cold STAT1 or Sp1 oligonucleotides. Cold AP-1 oli-
gonucleotides (AP-1 sense 59-AGCTTCGCTTGATGACT-
CAGCCGGAA 239 and antisense 59-AATTCTTCCGGCT-
GAGTCATCAAGCG 239) were used as negative controls.
DNA-protein complexes were separated on a 6% nondenaturing
polyacrylamide gel at 200 V. The gel was fixed and dried, and
DNA-protein complexes were visualized by autoradiography.
Chromatin Immunoprecipitation (ChIP) Assay—ChIP assay
was performed essentially as described previously (30). Briefly,
2 3 106 cells were fixed in 1% formaldehyde for 15 min to
cross-link DNA with associated proteins. The cross-linking
reaction was terminated by the addition of 125mM glycine, and
cells were then washed and harvested in PBS containing prote-
ase/phosphatase inhibitors. The pelleted cells were lysed on ice
in a buffer containing 50 mM Tris-HCl, pH 8.1, 1% SDS, 10 mM
EDTA, and protease/phosphatase inhibitors. Cells were soni-
cated for 10 s (six times). DNA was fragmented in a range of
200–1000 bp. Equal amounts of chromatin were diluted in
ChIP buffer (16.7mMTris-HCl, pH 8.1, 0.01% SDS, 1.1%Triton
X-100, 1.2 mM EDTA, and 167 mM NaCl) and incubated over-
night at 4 °C with anti-STAT1 or anti-Sp1 antibodies (Abcam,
Cambridge, MA) or control rabbit IgG (Cell Signaling Inc.),
followed by 1 h of incubation with salmon spermDNA/protein
A-agarose beads. 10% of the sample was kept as input. Protein
A-agarose beads pellets were sequentially washed with a low
salt buffer (20 mM Tris-HCl, pH 8.1, 0.1% SDS, 1% Triton
X-100, 2 mM EDTA, and 150 mM NaCl), a high salt buffer (20
mMTris-HCl, pH 8.1, 0.1% SDS, 1%Triton X-100, 2mMEDTA,
and 500 mM NaCl), LiCl wash buffer (10 mM Tris-HCl, pH 8.1,
0.25 M LiCl, 1% Nonidet P-40, 1% deoxycholate, 1 mM EDTA),
and TE buffer (10 mM Tris-HCl, pH 8.0, and 1 mM EDTA).
Protein-DNA complexes were eluted in a buffer containing 1%
SDS and 0.1 M NaHCO3. Cross-linking was reversed with 200
2 The abbreviations used are: qPCR, quantitative PCR; MTM, mithramycin A;
AZA, 5-aza-29-deoxycytidine.
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mMNaCl overnight at 65 °C, followed by incubation in a buffer
containing 40mMTris-HCl, pH 6.5, 10mMEDTA, and 20mg of
proteinase K for 2 h at 55 °C. DNA was then extracted with
QIAquick PCR purification kit (Qiagen) and analyzed by PCR.
For STAT1-2/3 sites 2880/2869 and 2793/782 bp, we used
primers 59-CGCCAGCTCTCCACCGTTGTC (forward) and
59-GTCGGTGTGCGAGCGAGTCTCC (reverse). For Sp1-2
site2668/2659 bp,we used primers 59-GGAGACTCGCTCG-
CACACCGAC (forward) and 59-GCAGGGACTGCGACT-
CAGCG (reverse). For Sp1-5 site 2347/2338 bp, we used
primers 59-GTGGGGCTTGTGGATTTTTA (forward) and
59-AGATTTCAACCCGGATCCTC (reverse). For Sp1-6/7 sites
2269/2260 bp and2256/2247 bp, we used primers 59-CGCT-
GAGTGTGCGAAGAGGATCC (forward) and 59-CCGGC-
GCTTACCTACCTTTCCG (reverse).
Cell Migration Assay—Cell migration was determined with a
Boyden chamber, as described previously (31). Briefly, MCF-7
cells (33 104 cells/well) were seeded in the upper compartment
of a Boydenchamber (NeuroProbe).A12-mmporepolycarbonate
filter (NeuroProbe) coated overnight with type IV collagen in cold
PBS was used to separate the upper and lower compartments. In
the lower chamber, 0.1% BSA/DMEM with or without FBS (5%)
was used. After 24 h of incubation at 37 °C, nonmigrating cells on
the upper side of the membrane were wiped off the surface, and
migrating cells on the lower side of the membrane were fixed,
stained with DIFFQuik Stain Set (Dade Behring), and counted by
contrast microscopy in five independent fields.
Statistical Analysis—Results are the means6 S.E. of at least
three individual experiments. Student’s t test was used for sta-
tistical comparison. A p value , 0.05 was considered statisti-
cally significant.
RESULTS
Overexpression of PKCe in Breast Cancer Cells and Initial
Characterization of the PRKCE Promoter—PKCe, a kinase
broadly implicated in tumorigenesis and metastasis, is overex-
pressed in multiple cancers. Elevated PKCe levels have been
associated with poor outcome in prostate, breast, lung, and
head and neck cancer (22, 24, 32, 33); however, themechanisms
behind the control of PKCe expression remain to be estab-
lished. A comparative analysis of PKCe protein levels byWest-
ern blot shows that this kinase is overexpressed in multiple
breast cancer cell lines (MCF-7, T-47D, BT-474, HCC-1419,
MDA-MB-231, MDA-MB-453, and MDA-MB-468 cells) rela-
tive toMCF-10A cells, an immortalized nontumorigenic mam-
mary cell line (Fig. 1A). qPCR assays also revealed significantly
higher PKCemRNA levels in breast cancer cells comparedwith
MCF-10A cells (Fig. 1B). To determinewhether overexpression
of PKCe is associated with altered mRNA stability, we assessed
mRNA levels at different times after treatment with the tran-
scriptional inhibitor actinomycin D. As shown in Fig. 1C, the
decay in mRNA levels is essentially the same in breast cancer
cell lines (MCF-7, T-47D, and MDA-MB-453) and MCF-10A
cells. Thus, the differential expression of PKCe may involve a
dysregulation of transcriptional mechanisms. Likewise, and in
agreement with previous studies (18, 27), PKCe is overex-
pressed in lung and prostate cancer cell lines relative to corre-
sponding normal “nontransformed” cell lines (Fig. 1A).
To investigate the transcriptional mechanisms involved in
PKCe expression, we cloned a 2.1-kb fragment of the human
PRKCE gene from genomic DNA using PCR. This fragment
includes 1933 bp of the putativePRKCE promoter aswell as 219
bp after the putative transcription start site. We also cloned
four fragments encompassing shorter regions of the putative
PRKCE promoter (1416/1219 bp, 808/1219 bp, 320/1219
bp, and 105/1219 bp, respectively). The different DNA frag-
ments were subcloned into the pGL3-enhancer luciferase
reporter vector to generate the plasmids pGL321933/1219,
pGL321416/1219, pGL32808/1219, pGL32320/1219, and
pGL32105/1219. Plasmids were transiently transfected into
MCF-7 breast cancer cells along with pRL-TK (Renilla lucifer-
ase vector) for normalization of transfection efficiency. The
pGL321416/1219 reporter construct exhibited the highest
luciferase activity, which was ;40 times higher than pGL3-
enhancer empty vector, therefore confirming that it possesses
functionalPRKCEpromoter activity. A progressive loss in lucif-
erase activitywas observedupondeletions of fragments21416/
2809, 21416/2321, and 21416/2106. A significant loss of
promoter activity was also observed with pGL321933/1219,
suggesting repressive transcriptional elements within the
21933/21417 bp region (Fig. 1D). A comparison of PRKCE
promoter activity in different cell lines using pGL321416/
1219 revealed a manifest elevation in luciferase activity in
breast cancer cells relative to normal immortalized MCF-10A
cells. Similarly, lung and prostate cancer cell lines exhibited
higher promoter activity than the corresponding nontumori-
genic counterparts (Fig. 1E).
A comparative analysis of PRKCE gene expression in 48 breast
cancer cell lines (24 luminal-like and 24 basal-like) obtained from
three independent studies (GSE10843,GSE12777, andGSE41445)
was performed using inSilicoDb and inSilicoMerging R/Biocon-
ductor packages (29). This analysis showed no statistically signifi-
cant differences between luminal and basal-like breast cancer cell
lines (p5 0.673) (Fig. 1F).
Differential Expression of PKCe Is Not Related to Promoter
Methylation—It is well established that epigeneticmechanisms
control the expression of key oncogenic and tumor-suppress-
ing proteins. To determine whether methylation of the PRKCE
promoter could be implicated in the differential expression
between normal mammary and breast cancer cells, we first
examined if the promoter was rich in CpG islands using the
Methyl Primer Express software (Applied Biosystems). This
analysis revealed two regions in the PRKCE promoter that were
very rich in CpG islands, a proximal region between 22.6 and
10.9 kb and a distal region between28.9 and27.7 kb (Fig. 2A).
To determine whether the reduced PKCe expression in MCF-
10A cells could be due to promoter methylation, we used the
demethylating agent 5-aza-29-deoxycytidine (AZA). qPCR
analysis revealed that PKCe mRNA levels remain essentially
unchanged inMCF-10A cells treated with different concentra-
tions of AZA, either in the presence or absence of the HDAC
inhibitor trichostatin A (Fig. 2B). A similar treatment in MCF-
10A cells caused a significant rescue in the expression of the
oncogenic protein P-Rex1, a gene that is regulated by methyla-
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tion.3 Therefore, overexpression of PKCe in breast cancer cells
does not seem to be related to demethylation of the PRKCE
gene promoter.
Identification of Key Transcriptional Regions in the Human
PKCe Promoter—To characterize the human PRKCE promoter
in more detail and to identify positive regulatory elements
responsible for transcriptional activation, a series of 59-uni-
directional deletions was generated from the pGL321416/
1219 luciferase reporter vector using the Erase-a-Base sys-
tem. The resulting constructs were transfected into MCF-7
cells, and luciferase activity was determined. Fig. 3 shows
that promoter activities of pGL321319/1219, pGL321224/
1219, pGL321121/1219, pGL321032/1219, pGL321028/
1219, and pGL32921/1219 constructs were essentially simi-
lar to that of pGL321416/1219. However, a significant
3 L. Barrio-Real, L. G. Benedetti, N. Engel, Y. Tu, S. Cho, S. Sukumar, and M. G.
Kazanietz, in press.
FIGURE 1. ElevatedPKCe expression andPRKCEpromoter activity in breast cancer cells.A, PKCe expression in immortalized “normal”MCF-10Amammary
epithelial cells, RWPE-1prostate epithelial cells, andHBEC lungepithelial cells, aswell as inbreast, prostate, and lungcancer cell lines, asdeterminedbyWestern
blot. Similar results were observed in three independent experiments. B, PKCemRNA levels inmammary cell lines, as determined by qPCR. Data are expressed
as mean 6 S.E. of three independent experiments. *, p , 0.05; **, p , 0.01 versus MCF-10A cells. C, PKCe mRNA stability in MCF-10A, MCF-7, T-47D, and
MDA-MB-453 cell lines. Cellswere treatedwith actinomycinD (2.5mg/ml), andRNAwasextractedatdifferent times. PKCemRNA levelsweremeasuredbyqPCR.
Data are expressed as percentage relative to levels at t5 0 and represent the mean6 S.E. of three independent experiments. D, analysis of PRKCE promoter
activity. Luciferase reporter plasmids pGL321933/1219, pGL321416/1219, pGL32808/1219, pGL32320/1219, pGL32105/1219, and pGL3 empty vector
were transfected intoMCF-7 cells along with the pRL-TK Renilla luciferase vector. Luciferase activity was determined 48 h later. Data are expressed asmean6
S.E. of three independent experiments. *, p, 0.05; **, p, 0.01 versus pGL3 vector. E, luciferase activity in normal and cancer cells was determined 48 h after
transfection of different cell lines with pGL321416/1219 along with the pRL-TK Renilla luciferase vector. Data are expressed as mean 6 S.E. of three inde-
pendent experiments. *, p, 0.05; **, p, 0.01 versus nontumorigenic cells. F, PKCe expression profile based on a compiled dataset of breast cancer cell lines
(BCCLs) (left panel), which show no significant statistical differences between those of luminal and basal origin (p5 0.673) (right panel).
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reduction in transcriptional activity was observed upon serial
deletions starting from bp 2887. Indeed, pGL32887/1219,
pGL32873/1219, and pGL32819/1219 display 77, 58, and
37% activity, respectively, compared with that of pGL321416/
1219. No additional changes in reporter activity were observed
with pGL32808/1219. Constructs pGL32796/1219 and
pGL32777/1219 display slightly lower luciferase activity than
pGL32808/1219.Luciferaseactivitydrops significantlywithcon-
structs pGL32320/1219 (91% reduction) and pGL32105/1219
(98% reduction). To summarize these initial observations, the
deletional analysis delineated two prominent regions in the
PRKCE promoter containing positive regulatory elements that
we defined as region A (2777 to2105 bp) and region B (2921
to2796 bp). In subsequent sections, amore detailed character-
ization of the cis-acting elements in these two regions will be
shown.
Analysis of Region A Revealed a Crucial Role for Sp1 in PKCe
Transcription—To identify putative transcriptional elements
in region A of the PRKCE promoter, we initially used the
PROMO software. This analysis revealed the presence of seven
putative Sp1-responsive elements that we named Sp1-1 (the
most distal site, bp2716 to2707) to Sp1-7 (the most proximal
site, bp 2256 to 2247) (Fig. 4A, left panel). The putative
Sp1-binding sequences are shown in Fig. 4A, right panel. To
define the relevance of the different Sp1-binding sites,
additional truncated mutants for region A were generated
using pGL32777/1219 as a template (pGL32644/1219,
pGL32531/1219, and pGL32401/1219), and we examined
for their luciferase activity upon transfection into MCF-7 cells.
Fig. 4B shows that deletion of region comprising bp 2777 to
2664 (which includes Sp1-1 and Sp1-2 sites) caused a 65%drop
in luciferase activity. No additional changes in reporter activity
were observed upon deletions of regions comprising bp2644/
2532,2644/2402, and2644/2321,which include sites Sp1-3,
Sp1-4, and Sp1-5. However, when fragment 2320/2105
(which includes Sp1-6 and Sp1-7) was deleted, an additional
reduction in luciferase activity was observed. These results sug-
gest that multiple Sp1 sites in region A contribute to the tran-
scriptional activity of the PRKCE promoter.
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To further determine the contribution of the different Sp1
sites in the transcriptional activation of the PRKCE promoter,
we performed site-directed mutagenesis of these sites in the
context of the pGL32777/1219 construct. Essential residues
GGCG in Sp1 sitesweremutated toTTAT, and luciferase activ-
ities of the corresponding constructs were determined after
transfection into MCF-7 cells. As shown in Fig. 4C, mutation
of Sp1-1 in pGL2777/1219 had no effect; however, mutation
of Sp1-2 caused a 62% reduction in reporter activity. Sp1-6 and
Sp1-7 were only 4 bp apart, and therefore we decided tomutate
them together. When we mutated Sp1-6/7 in pGL32777/
1219, a significant reduction (50%) in luciferase activity was
observed. We further mutated Sp1-6/7 sites in pGL32320/
1219, and observed a significant reduction in reporter activity
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compared with the wild-type pGL32320/1219 construct.
However, it did not reach complete inhibition, thus arguing for
the presence of other relevant transcriptional element(s) within
the 2320/2105 region that remain to be identified. The dele-
tional and mutational analyses of region A indicate that multi-
ple Sp1 sites control the transcriptional activation of the
PRKCE promoter.
To confirm the relevance of the Sp1-binding sites in tran-
scriptional activation of the PRKCE gene, we used a number of
additional approaches. First, we examined the effect of mithra-
mycin A (MTM), an agent that prevents binding of Sp1 to its
transcription binding site (34, 35). As shown in Fig. 4D, MTM
markedly reduced luciferase activity of reporters pGL32777/
1219 and pGL32320/1219. As a second approach, and to
address whether Sp1 proteins associate with the PRKCE pro-
moter in vivo, we performed a chromatin immunoprecipitation
(ChIP) assay using an anti-Sp1 antibody. As a negative control,
we used IgG. Three sets of primers were utilized in these exper-
iments as follows: one encompassing bp2772 to2615 (for site
Sp1-2); a second encompassing bp 2320 to 2186 (for Sp1-6
and Sp1-7), and a third for bp 2443 to 2286 (for site Sp1-5).
Sp1 immunoprecipitation revealed the expected bands for
regions 2772/2615 and 2320/2186, and no band was
observed for region 2443/2286 (Fig. 4E). Thus, the Sp1 tran-
scription factor binds in vivo to the sites identified in our dele-
tional/mutational analysis. Finally, to confirm the involvement
of Sp1, we knocked down this transcription factor using RNAi.
Sp1 RNAi depletion from MCF-7, T-47D, MDA-MB-231, and
BT-474 breast cancer cell lines significantly reduced the
expression of PKCe protein (Fig. 4F) and PKCe mRNA, as
determined by qPCR (Fig. 4G). Altogether, these results dem-
onstrate the relevance of Sp1 in transcriptional activation of the
PRKCE promoter.
STAT1-binding Sites in Region B Control PKCe Transcrip-
tional Activation—As established in the deletional analysis
shown in Fig. 3, region B located between bp 2921 and 2796
plays a positive role in transcriptional activation of the PRKCE
promoter. Analysis using the PROMO program revealed two
putative STAT1 sites in this region, which we named STAT1-1
(2916 to2905 bp) and STAT1-2 (2880 to2869 bp). There is
also a third STAT1 site (STAT1-3) at the edge of region B
(2793 to 2782 bp) (Fig. 5A). To determine the potential rele-
vance of these sites, essential residues TTTCC in STAT1 sites
were mutated to T¡C in pGL32921/1219. The resulting
mutant constructs were transfected into MCF-7 cells and
assessed for their luciferase reporter activity. As shown in Fig.
5B, mutation of the most distal STAT1 site (STAT1-1) had no
significant effect on luciferase activity. Conversely, mutation of
STAT1-2 site caused a 44% reduction in reporter activity. A
slight, yet statistically significant reduction in luciferase activity
was observed upon mutation of the STAT1-3 site. A double
mutant for STAT1-2 and STAT1-3 sites was generated, and its
activity was examined in MCF-7 cells, which revealed a 61%
reduction in luciferase activity compared with the pGL32921/
1219 construct. Therefore, the STAT1-2 and STAT1-3 sites
are involved in the regulation of PKCe promoter activity.
The program PROMO also identified two additional STAT1
sites outside region B, which were named STAT1-4 (2401 to
2390 bp) and STAT-5 (2227 to2216 bp). These two siteswere
actually located within the region A and in close proximity to
Sp1 sites (Fig. 5A). We mutated STAT1-4 and STAT1-5 sites
and found these mutations do not alter reporter activity (Fig.
5B), suggesting that only STAT1-2 and STAT1-3 sites are
involved in transcriptional control of the PRKCE promoter in
breast cancer cells.
Next, to confirm the relevance of STAT1 in the control of
PKCe transcriptional activity, we used RNAi (Fig. 5C). MCF-7
cells were transfected with a STAT1 SMARTpooltRNAi,
which caused.90% depletion in STAT1 levels (Fig. 5C, inset),
or a SMARTpoolt control RNAi and then transfected with the
pGL32921/1219 luciferase reporter vector. As expected from
the deletional andmutational analyses, silencing STAT1 inhib-
ited transcriptional activity of the PKCe reporter (54% reduc-
tion, which is in the same range as the reduction in activity
observed upon mutation of STAT1-2 and STAT1-3 sites com-
bined, see Fig. 5B). Moreover, when we assessed the activity of
the STAT1-2/3-mutated pGL32921/1219 construct, STAT1
RNAi depletion failed to cause an additional reduction in lucif-
erase activity (Fig. 5C), thus confirming the importance of
STAT1-2 and STAT1-3 sites in the control of PRKCE promoter
activity. To further confirm the relevance of the STAT1 sites,
we usedChIP. For this analysis, we used a set of primers encom-
passing2949 to2751 bp in the PRKCE promoter, a region that
includes both STAT1-2- and STAT1-3-binding sites. Results
shown in Fig. 5D revealed a band of the expected size (199 bp)
when an anti-STAT1 antibodywas used in the immunoprecipi-
tation, whereas no band was observed using control IgG, thus
suggesting direct binding of STAT1 to the2949 to2751-bp
promoter region. Furthermore, STAT1 RNAi depletion
from MCF-7 cells caused a significant reduction in PKCe
mRNA (Fig. 5E) and protein levels (Fig. 5F). Altogether,
these results indicate that STAT1-2- and STAT1-3-binding
sites are involved in the transcriptional control of the PRKCE
promoter. An additive effect between STAT1 RNAi depletion
and MTM treatment was observed (Fig. 5F).
STAT1 and Sp1 Contribute to the Elevated PKCe Transcrip-
tional Activity in Breast Cancer Cells—Once we identified rel-
evant Sp1 and STAT1 sites in the PRKCE promoter, we asked if
these sites mediate PKCe up-regulation in breast cancer cells
relative to nontumorigenic mammary cells. To address this
issue, we compared the activities of the different deleted report-
ers between MCF-7 versus MCF-10A cells. As shown previ-
ously in Fig. 1E with reporter pGL321416/1219, activity of
pGL32921/1219 reporter was also higher in MCF-7 cells rel-
ative toMCF-10A cells (Fig. 6A). Deletion of fragment2921 to
2777 bp, which includes STAT1-2/3 sites in region B, dimin-
ished luciferase activity in MCF-7 cells by 61%, an effect that
was not seen in MCF-10A cells (Fig. 6, A and B). To verify the
relevance of the STAT1 sites in PKCe up-regulation in breast
cancer cells, we compared the activity of pGL32921/1219
(wild type) versus pGL32921/1219 (STAT-2/3-mutated) in
MCF-7 and MCF-10A cells. Whereas mutation of STAT1-2
and STAT1-3 sites failed to reduce reporter activity in MCF-
10A cells, a marked reduction in activity (;70% reduction) was
observed inMCF-7 cells (Fig. 6C) as well as in T-47D cells (data
not shown). To validate the relevance of the STAT1-2/3 sites in
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PKCe up-regulation, we used an EMSA approach. Nuclear
extracts from MCF-10A, MCF-7, or T-47D cells were incu-
bated with 25-bp double-stranded radiolabeled probes for
either the STAT1-2 site or a standard STAT1 binding consen-
sus. As shown in Fig. 6D, a shift protein-DNA complex band
was detected after incubation of nuclear extracts from either
probe both in MCF-7 (lanes 3 and 6) and T-47D cells (lanes 4
and 7). However, this effect was not seen in nontumorigenic
MCF-10A cells (Fig. 6D, lanes 2 and 5). The shift band was
competed by co-incubation with an excess (50-fold molar) of
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unlabeled probes for either STAT1-2 (Fig. 6D, lane 8) or a
standard STAT1-binding consensus sequence (lane 9) but not
with an excess unlabeled probe for AP-1 (lane 10), thereby con-
firming the specificity of the interaction. A similar result was
observed using a probe for site STAT1-3 (data not shown).
Thus, STAT1-2/3 sites contribute to the up-regulation of PKCe
transcriptional activity in breast cancer cells.
Next, we carried out similar experiments to determine
whether the Sp1-2 site was implicated in PKCe up-regulation in
breast cancer cells relative to nontumorigenic MCF-10A cells.
As shown in Fig. 6A, deletion of fragment 2777 to 2531 bp,
which includes relevant Sp1-2 site in region A (position 2668
to 2659), reduced luciferase reporter activity in MCF-7 cells
but not in MCF-10A cells. No additional changes were found
upon deletion of region2531 to2320 bp in either cell line. To
verify the relevance of the Sp1-2 site in PKCe up-regulation in
breast cancer cells, we compared the activity of pGL32777/
1219 (wild type) versus pGL32777/1219 (Sp1-2-mutated) in
MCF-7 and MCF-10A cells. Fig. 7A shows that mutation of
Sp1-2 significantly reduced luciferase activity in MCF-7 cells,
whereas this mutation had no effect in MCF-10A cells. As
expected, mutation of the Sp1-1 site, which was dispensable for
transcriptional activity (see Fig. 4C), did not alter reporter
activity in MCF-7 or MCF-10A cells. To further verify the rel-
evance of the Sp1-2 site in PKCe up-regulation in breast cancer,
we used an EMSA approach. Nuclear extracts fromMCF-10A,
MCF-7, or T-47D cells were incubated with radiolabeled
probes for either the Sp1-2 site or a standard Sp1 binding con-
sensus. As shown in Fig. 7B, a shift protein-DNA complex band
was detected after incubation of nuclear extracts from either
probe both in MCF-7 (lanes 3 and 6) and T-47D cells (lanes 4
and 7) but not in nontumorigenic MCF-10A cells (lanes 2 and
5). The specificity of the interaction was confirmed by compe-
tition of the shift band with an excess (50-fold molar) of unla-
beled probes for either Sp1-2 (Fig. 7B, lane 8) or a standard Sp1
binding consensus (lane 9) but not with an unlabeled probe for
AP-1 (lane 10).
We also found that deletion of fragment 2320 to 2105 bp,
which comprises proximal Sp1-binding sites (Sp1-6/7), essen-
tially abolished luciferase activity both inMCF-7 andMCF-10A
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cells (see Fig. 6A). Mutation of Sp1-6/7 sites significantly
reduced the activity of the pGL32320/1219 reporter inMCF-7
andMCF-10A cells (Fig. 7C), suggesting that Sp1-6/7may con-
trol constitutive expression both in normal and cancer cells.
The large drop in activity by deletion of fragment2320 to2105
bp compared with the mutation of Sp1-6/7 sites (Fig. 6A see
also Fig. 3) argues for additional elements in this region control-
ling basal promoter activity.
PKCe Controls Its Own Expression in Breast Cancer Cells—
There is evidence that PKCe controls the phosphorylation sta-
tus and activity of STAT1 in several cellular models (36–38).
Ser-727 phosphorylation in STAT1 is required for its maximal
transcriptional activity (39). Likewise, we found that PKCe con-
trols the activation status of STAT1 in breast cancer cells, as
judged by the reduction in phospho-Ser-727-STAT1 levels
upon PKCe depletion in MCF-7, T-47D, MDA-MD-231,
MDA-MB-453, andMDA-MB-468 breast cancer cell lines (Fig.
8A). Similar results were observed in prostate and lung cancer
models (data not shown). Treatment of MCF-7 cells with the
pan-PKC inhibitor GF 109203X or the specific PKCe inhibitor
eV1-2 also reduced phospho-Ser727-STAT1 levels (Fig. 8B).
Given our finding that STAT1 transcriptionally regulates
PKCe expression, we speculated that PKCe controls its own
expression via STAT1. Treatment of MCF-7 cells with eV1-2
(Fig. 8C) or GF 109203X (data not shown) significantly
reduced pGL321416/1219 luciferase reporter activity. To
examine the potential involvement of PKCe in controlling its
own promoter activity, we used PKCe RNAi. PKCe expression
was silenced from MCF-7 cells by .90% upon delivery of two
different PKCe RNAi duplexes (e1 and e2), as we did previously
in other models (18, 25). Notably, luciferase activity of the
pGL321416/1219 reporter was significantly decreased in
PKCe-depleted MCF-7 cells (Fig. 8D), indicating that the ele-
vated levels of PKCe in breast cancer cells positively control its
own expression at a transcriptional level. The results described
above argue for a mutual dependence between PKCe expres-
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sion and STAT1 activation. We decided to formally test this
hypothesis in mammary cellular models (Fig. 8E). We observed
that normal immortalized MCF-10A cells, which express low
PKCe levels, display low levels of phospho-Ser-727-STAT1.
Conversely, breast cancer cell lines with very high PKCe levels
(MCF-7, T-47D, MDA-MB-231, MDA-MB-453, and MDA-
MB-468) show high levels of phospho-Ser-727-STAT1. Breast
cancer cell lines with intermediate PKCe levels (BT-474 and
HCC-1419) show intermediate phospho-Ser-727-STAT1 sig-
nals by Western blot. Upon densitometric quantification of
Western blots, we found a strong correlation between PKCe
and phospho-Ser-727-STAT1 levels (R25 0.90) (Fig. 8F). Alto-
gether, these results argue for a positive feedback between
PKCe expression and STAT1 activation in breast cancer cells.
PKCeMediates Migration of Breast Cancer Cells—PKCe has
been implicated in tumor initiation, progression, and metasta-
sis (22, 25, 27). Fig. 9A shows that PKCe RNAi depletion signif-
icantly reduced the motility of cells in response to 5% FBS, as
determined with a Boyden chamber. The Sp1 inhibitor MTM,
which significantly reduces PKCe expression (Fig. 9B, see also
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Figs. 4F and 5F) also significantly impaired MCF-7 cell migra-
tion (Fig. 9A). Adenoviral overexpression of PKCe overcame
the effect of PKCe RNAi on cell migration. The impaired cell
migration caused by MTM could be partially restored by
adenoviral overexpression of PKCe, thus arguing that the
expression levels of PKCe are crucial for the ability of breast
cancer cells to migrate.
DISCUSSION
PKCe, a member of the novel PKCs, has been extensively
characterized as a mitogenic/survival kinase that activates
pathways linked to malignant transformation and metastasis,
including Ras/Raf/Erk, PI3K/Akt, and NF-kB (17, 18). Pharma-
cological inhibition or RNAi silencing of PKCe expression
impairs the ability of cancer cells to form tumors in nude mice
andmetastasize to distant sites (22). Overexpression of PKCe in
nontransformed cells confers growth/survival advantage or
leads to malignant transformation (16). In an in vivo scenario,
transgenic overexpression of PKCe in the mouse prostate leads
to a preneoplastic phenotype, and skin transgenic overexpres-
sion of this kinase leads to the development of metastatic squa-
mous carcinoma (40). Therefore, there is significant evidence
that overexpression of PKCe is causally associated with the
development of a malignant and metastatic phenotype. This is
highly relevant in the context of human cancer, as a vast major-
ity of cancers displays PKCe up-regulation, including breast,
prostate, and lung cancer (18, 22, 25). Increased PKCe expres-
sion in breast cancer correlates with high histological grade,
positive ErbB2/Her2 status, and hormone-independent status
(22). Despite the wealth of functional information regarding
PKC and cancer, both in vitro and in vivo, as well as the estab-
lishedmechanistic links with proliferative pathways, the causes
behind the up-regulation of PKCe in human cancer remained
elusive.
In this study we report that PKCe up-regulation in breast
cancer cells occurs through dysregulation of transcriptional
mechanisms. An ;1.6-kb fragment of human genomic DNA
encompassing the 59-flanking region and part of the first exon
(21.4 to 10.2 kb) of the PRKCE gene was isolated and cloned
into a luciferase reporter vector. This fragment displayed sig-
nificantly higher transcriptional activity when expressed in
breast cancer cells relative to normal immortalized MCF-10A
cells. However, the elevated PKCe mRNA levels in breast can-
cer cells do not seem to be related to changes inmRNAstability.
Our deletional andmutagenesis studies combinedwith in silico
analysis identified key positive regulatory cis-acting Sp1 and
STAT1 elements in two regions (regions A and B) that we
defined as responsible for the up-regulation of PKCe transcrip-
tional activation in breast cancer cells, and their functional rel-
evance was confirmed by EMSA and ChIP. A region that nega-
tively regulates transcription located upstream from the 1.6-kb
fragment, specifically between21.4 and21.9 kb, was also iden-
tified. Studies to dissect and characterize these negative ele-
ments are underway.
From the seven putative Sp1-responsive elements located in
regionAof thePRKCE gene, only one located between bp2668
and 2659 contributes to the differential overexpression of
PKCe in MCF-7 cells. The two most proximal Sp1 sites located
in positions 2269/2260 and 2256/2247 contribute to tran-
scriptional activation of the PRKCE gene both in MCF-7 and
MCF-10A cells, suggesting that these sites control basal expres-
sion both in normal and cancer cells. The Sp1 transcription
factor has been widely implicated in cancer and is up-regulated
in human tumors. For example, it has been reported that Sp1
protein and binding activity are elevated in human breast car-
cinoma (41, 42). Sp1 is highly expressed both in estrogen recep-
tor-positive and -negative cell lines (43), and its depletion using
RNAi leads to reduced G1/S progression of breast cancer cells
(44). Sp1 controls the expression of genes implicated in breast
tumorigenesis and metastatic dissemination, including ErbB2
(45), EGF receptor (46), IGF-IR (47, 48), VEGF (49, 50), cyclin
D1 (51), and urokinase-type plasminogen activator receptor
(42). The transcription factor Sp1 binds to GC-rich motifs in
DNA, and DNA methylation of CpG islands can inhibit Sp1
binding to DNA (52–54). Nevertheless, our studies show that
the demethylating agent AZA could not up-regulate PKCe
mRNA levels in MCF-10A cells. Thus, despite the presence of
CpG-rich regions in the PRKCE promoter, repression bymeth-
ylation does not seem to take place in normalmammary cells. It
is interesting that a recent study in ventricular myocytes
showed PRKCE gene repression through methylation of Sp1
sites via reactive oxygen species in response to norepinephrine
or hypoxia (55, 56), suggesting that epigenetic regulation of the
PRKCE gene can take place in some cell types under specific
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conditions. Notably, functional Sp1-binding sites have been
identified in the promoters of PKCb and PKCd isozymes, and
Sp1 binding to thePKCb gene is repressed by hypermethylation
and re-expressed by AZA treatment (57, 58).
The most notable characteristic of region B in the PRKCE
promoter is the presence of three STAT1-binding sites. Two of
those sites located in position2880/2869 and2793/2782 are
functionally relevant in breast cancer cells. Indeed, a marked
reduction (.50%) of promoter activity was observed upon
mutation of these sites. Moreover, STAT1 RNAi caused a sig-
nificant reduction in PKCemRNA and protein levels. The ele-
vated PKCe levels in breast cancer cell lines strongly correlate
with the activation status of STAT1. Activation of STAT tran-
scription factors involves the phosphorylation of tyrosine resi-
dues either by JAK or independently of JAK by tyrosine kinase
receptors such as EGF receptor (59). To date, the role of STAT1
in cancer progression remains controversial. Based on its
canonical role in IFN-g signaling and loss of function studies
using STAT1 knock-out mice, it has been postulated that
STAT1 acts as a tumor suppressor (60). However, a large num-
ber of studies link STAT1with tumor promotion as well as with
resistance to chemotherapy and radiotherapy. Moreover,
STAT1 is up-regulated and/or hyperactive in many cancers,
including breast cancer (61, 62). STAT1 up-regulation in
human breast cancer is associated with metastatic dissemina-
tion and poor outcome in patients (62–64). In addition, STAT1
overexpression has been linked to aggressive tumor growth and
the induction of proinflammatory factors, whereas STAT1
knockdown delays tumor progression (61). Inhibition of
STAT1 in breast cancer prevents the homing of suppressive
immune cells to the tumor microenvironment and enables
immune-mediated tumor rejection (61). ErbB receptor activa-
tion, a common event in human breast cancer, significantly
enhances STAT1 expression (65). In othermodels, such asmel-
anoma, suppression of STAT1 expression reduces cell motility,
invasion, andmetastatic dissemination (66). STAT1 expression
correlates with resistance to chemotherapeutic agents such as
doxorubicin, docetaxel, and platinum compounds and is ele-
vated in resistant tumors (67–72). STAT1 also promotes
radioresistance of breast cancer stem cells (73). Notably, PKCe
has been linked to chemo- and radio-resistance (19, 20); thus, it
is conceivable that PKCe up-regulation mediated by STAT1
may play a role in this context. The fact that PKCe controls its
own expression in breast cancer cells suggests the possibility of
a vicious cycle that contributes to the overexpression of this
kinase. It is unclear at this stage what pathways are controlled
by PKCe that lead to its own transcriptional activation. One
possibility is that PKCe controls the expression of factors that
influence STAT1 activation status, such as growth factors or
cytokines that signal via this transcription factor.
In summary, this study identified relevant mechanisms that
control PKCe expression in breast cancer cells. As PKCe over-
expression has been linked to an aggressive phenotype and
metastatic dissemination, our study may have significant
therapeutic implications. In this regard, several studies sug-
gested that targeting PKCe could be an effective anticancer
strategy. Indeed, the PKCe translocation inhibitor eV1-2 has
anti-tumorigenic activity in non-small cell lung cancer and
head and neck squamous cell carcinomamodels (25, 27). More
recently, an ATP mimetic inhibitor with selectivity for PKCe
was shown to impair the growth of MDA-MB-231 breast can-
cer xenografts in mice as well as to reverse Ras-driven and epi-
thelial-mesenchymal transition-dependent phenotypes in
breast cancer cells (26). Thus, targeting PKCe or the mecha-
nisms responsible for its up-regulation in tumors may provide
novel means for the treatment of cancer types driven by PKCe
overexpression.
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